Full-Time

Associate Director

Global Insurance and Risk Management

Updated on 9/3/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$154.4k - $242.6k/yr

+ Short-term and/or long-term incentives + 401(k) company match

Cambridge, MA, USA

Hybrid

Hybrid role with at least 8 onsite days per month; candidates must live within commuting distance of the Cambridge office.

Bachelor's

Category
Insurance

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • Strong experience in an insurance risk management role in the insurance or risk industry is required.
  • Strong understanding of global insurance programs and client servicing is required.
  • Knowledge and expertise of the global insurance markets is required.
  • Knowledge of global insurance legislation, regulations, and local market practice is required.
  • A strong network within United States broking and insurer communities is required.
  • Strong organizational and project management skills are required.
  • Strong communication and interpersonal skills, including the ability to build and manage senior internal and external relationships, are required.
  • Adaptability and the capacity to work under pressure are required.
  • Strong technical insurance knowledge is required.
  • Decision-making and strong negotiation skills are required.
  • Emotional intelligence is required.
  • The ability to work independently, with guidance in the most complex situations, is required.
  • International travel is required from time to time.
  • Candidates must live within a commutable distance of Takeda's Cambridge, Massachusetts office.
Responsibilities
  • Work closely with the Head of Global Insurance and Risk Management to support the development, implementation, and management of the Global Risk Financing Strategy and ensure alignment with the overall group strategy.
  • Lead specific Global Insurance Programs and the end-to-end claims lifecycle.
  • Ensure compliance with all global regulations and legislation.
  • Serve as a subject matter expert for the business in specific areas of Global Insurance responsibilities.
  • Develop, modify, and execute company policies and solve unique and complex problems affecting operations, disciplines, business units, business functions, and regions.
  • Proactively manage appointed United States global brokers and drive performance to service level agreements.
  • Ensure that Takeda employees, assets, and liabilities are protected in line with the global insurance placement strategy.
  • Lead negotiation of terms and implementation of key United States insurance programs and selected global insurance programs, including Workers Compensation, Automobile Liability, and Cyber Liability.
  • Manage the United States construction and capital expenditure risk approach and place project policies.
  • Oversee and act as an escalation point for other Global Insurance Programs and risk processes across the group.
  • Develop, implement, and lead the global premium allocation process in compliance with regulations and transfer pricing regulations.
  • Negotiate and oversee reinsurance agreements and key performance indicators.
  • Lead arrangements for stewardship meetings with lead insurers and other external partners.
  • Oversee annual underwriting data gathering and analysis for specific insurance programs.
  • Lead the strategy and production of underwriting submissions and support market presentations.
  • Proactively manage and grow long-term relationships with global insurers.
  • Serve as a Centre of Excellence on insurance policy and risk management issues and provide leadership and consultative expertise for a defined region or business.
  • Anticipate internal and external business challenges and regulatory issues and recommend process or service improvements.
  • Support discussions with external captive management on renewals, documentation, and claims processes.
  • Support the business with insurance clause review, indemnification, and limits of liability discussions.
  • Develop and update contract management guidance for Legal, Procurement, and other business stakeholders.
  • Provide direction on claims management strategy.
  • Evaluate small to large exposure claims with third-party administrators and claims handlers.
  • Liaise with Takeda Legal Counsel on claims management procedures and litigated claim strategy.
  • Communicate with site stakeholders and carrier claims teams.
  • Reconcile invoice and settlement payments.
  • Prepare open claims reports across multiple lines of business.
  • Conduct claims audits and review activities.
  • Support the Risk Engineering Program with fire risk engineering and support capital expenditure insurance processes and engineering plan reviews.
  • Lead and support Global Insurance and Risk Management risk projects.
  • Support the business on critical global contractual risk reviews and determine appropriate types and levels of insurance.
  • Oversee the development and implementation of insurance management information systems and use them to streamline insurance administration and reduce time and cost.
  • Deliver Global Insurance awareness training to key internal stakeholder groups.
  • Participate in and lead ad hoc risk management and other business projects as required.
  • Onboard and train Global Insurance and Risk Management team members when new members join or new initiatives and processes are implemented.
Desired Qualifications
  • A bachelor's degree with a concentration in Economics, Finance, Business, or Law is preferred.
  • Life Sciences sector experience is preferred.
  • Association of Chartered Insurance Institute qualification or part qualification, or strong and relevant alternative academic achievements, is desirable.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.